Dr. Robert A. Gatenby, MD

Dr. Gatenby practices at Moffitt Cancer Hospital in Tampa, Florida, part of Moffitt Cancer Center.

Dr. Gatenby's NPI, 1518071612, was assigned on August 18, 2006. Dr. Gatenby graduated from Perelman School of Medicine - Philadelphia in 1977. Dr. Gatenby's Arizona license number on file is 25441.

Dr. Gatenby's primary practice is Moffitt Cancer Hospital, at 12902 Magnolia Dr, Tampa, FL 33612. Dr. Gatenby also practices at H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc., 10920 McKinley Dr, Tampa, FL 33612.

Dr. Gatenby's primary practice is Moffitt Cancer Hospital in Tampa, Florida, part of Moffitt Cancer Center. The medical group on file is Moffitt Cancer Center. Dmand AI also links Dr. Gatenby to 1 more breast imaging center, 1 group practice or clinic and 1 hospital outpatient department, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Gatenby practices, 4 sites in all. Vendor and product names are available with a free account.

Diagnostic radiology is Dr. Gatenby's primary specialty in the NPI Registry, under taxonomy code 2085R0202X. Dr. Gatenby is board certified in diagnostic radiology by the American Board of Radiology. Dmand AI has Dr. Gatenby's licenses on file in 3 states: Arizona, Florida and Pennsylvania.

CMS data shows 1,753 Medicare services from Dr. Gatenby across 9 procedure codes in 2024, for 1,061 Medicare patients. Medicare paid $92,379 for them.

CMS counts 1,061 Medicare patients who saw Dr. Gatenby in 2024. The largest group is 65 to 74, with 522 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 8% are also on Medicaid. Their average risk score is 2.68, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Gatenby's median patient age at 69, with 49% women.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 88 out of 100 for Dr. Gatenby for performance year 2024, reported as part of a group. Dr. Gatenby accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 297 papers to Dr. Gatenby, published from 2005 to 2025. 2020 was the busiest year, with 19. The most frequent topics are Models, Biological, Neoplasm Invasiveness and Hydrogen-Ion Concentration. Dr. Gatenby has published most often in Cancer Res. Dr. Gatenby's most frequent co-authors are Philip Moldofsky, MD, Jingsong Zhang, MD and Marilyn Yuanxin Ma Bui, MD.

Dmand AI links Dr. Gatenby to 1 clinical trial. Conditions studied include Lung Neoplasms and Thoracic Neoplasms.

CMS Open Payments shows 6 general payments to Dr. Gatenby from 4 drug and device companies from 2018 to 2025. Food and beverage make up the largest share, 81% of the total. Sanofi and Genzyme US Companies paid the most, $365.

Dr. Gatenby graduated from Perelman School of Medicine - Philadelphia in 1977.

Dr. Gatenby is in network with 4 carriers, including Excellus BlueCross BlueShield, Molina and Aetna. Medicare plans come from the most carriers, 3. Check the plan with the practice before a visit.